Newfound Research’s AbbVie ABBV Stock Holding History

Newfound Research’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1	Closed	–	–	52
2020 Q1	$0	Hold	1	–	–	﹤0.01%	96
2019 Q4	$0	Buy	+1	New	+$83	﹤0.01%	143

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Newfound Research's ABBV Position: Q2 2020 in Review

Newfound Research sold out of AbbVie (ABBV) in Q2 2020, closing a stake of 1 share.

Newfound Research first reported a position in ABBV in Q4 2019 and held it in 2 quarters. The position peaked at $0 in Q1 2020. 2,411 funds tracked by Wall St. Rank hold ABBV as of Q2 2020.

Newfound Research reported no remaining AbbVie position as of Q2 2020 after selling out during the quarter.
Newfound Research sold 1 AbbVie share in Q2 2020.
Newfound Research first reported a position in AbbVie in Q4 2019 and held it in 2 quarters.
Newfound Research's AbbVie position peaked at $0 in Q1 2020.
2,411 funds tracked by Wall St. Rank held AbbVie as of Q2 2020.

Based on Newfound Research's 13F filing for Q2 2020, filed 10 Aug 2020.